Pure Global
NCT06354387

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

A Pilot Study of Alectinib (Alecensa) in Combination With Nivolumab (Opdivo) in the Treatment of Recurrent or Refractory Hepatocellular Carcinoma Patients Guided With Serum Level of RNase1 and Tumor Expression of PD-L1
China Medical University Hospital·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
Alectinib (Alecensa), Nivolumab (Opdivo)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
China Medical University Hospital
Location
Taichung, Taiwan
Timeline & enrollment
Phase
Phase 1
Start date
Feb 16, 2022
End date
Jun 01, 2025
Enrollment
8 participants
Primary outcome

Objective response rate(ORR)

Summary

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death and
 the second most deadly malignancy in Taiwan. Despite decades' intensive studies, surgery and
 local-regional chemo-embolization, radio-frequency ablation or radiation therapy remain the
 mainstay of HCC treatments.

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06354387
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06354387 through Pure Global AI's free database. This Phase 1 trial is sponsored by China Medical University Hospital and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 8 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.